Literature DB >> 34272590

Diagnostic performance of T2* gradient echo, susceptibility-weighted imaging, and quantitative susceptibility mapping for patients with multiple system atrophy-parkinsonian type: a systematic review and meta-analysis.

Su Jin Lim1, Chong Hyun Suh2, Woo Hyun Shim1, Sang Joon Kim1.   

Abstract

OBJECTIVES: To investigate the diagnostic performance of T2*-weighted gradient echo (GRE) imaging, susceptibility-weighted imaging (SWI), or quantitative susceptibility mapping (QSM) in differentiating multiple system atrophy-parkinsonian type (MSA-P) from Parkinson's disease (PD).
METHODS: A systematic literature search through the MEDLINE and EMBASE databases was performed, starting on September 8, 2020, to identify studies evaluating the diagnostic performance of putaminal hypointensity on T2* GRE or SWI and phase shift on QSM in differentiating MSA-P from PD. The pooled sensitivity and specificity were obtained using hierarchical logistic regression modeling and hierarchical summary receiver operating characteristic (HSROC) modeling. The pooled diagnostic yields of T2* GRE, SWI, or QSM among MSA-P patients were calculated using the DerSimonian-Laird random-effects model.
RESULTS: Twelve original articles with 985 patients were finally included. SWI was performed in seven studies, T2* GRE was performed in three studies, and QSM was performed in two studies. The pooled sensitivity and specificity were 0.65 (95% CI 0.51-0.78) and 0.90 (95% CI 0.83-0.95), respectively. The area under the HSROC curve was 0.87 (95% CI 0.84-0.90). The Higgins I2 statistic calculations revealed considerable heterogeneity in terms of both sensitivity (I2 = 72.12%) and specificity (I2 = 70.38%). The coupled forest plot revealed the threshold effect. For the nine studies in which area under the curve (AUC) was obtainable, the AUC ranged from 0.68 to 0.947, with a median of 0.819. The pooled diagnostic yield of T2* GRE, SWI, or QSM was 66% (95% CI 51-78%).
CONCLUSIONS: Putaminal hypointensity on T2* GRE or SWI and phase shift on QSM might be a promising diagnostic tool in differentiating MSA-P from PD. Further large multicenter prospective study is warranted. KEY POINTS: • Three different index tests, definitions of positive image findings, thresholds, the way how to draw ROIs, reference standard, and MRI parameters could affect the heterogeneity of the study. • The pooled sensitivity and specificity were 0.65 (95% CI 0.51-0.78) and 0.90 (95% CI 0.83-0.95), respectively. • The pooled diagnostic yield of T2* GRE, SWI, or QSM was 66% (95% CI 51-78%).
© 2021. European Society of Radiology.

Entities:  

Keywords:  Magnetic resonance imaging; Multiple system atrophy; Parkinson disease

Mesh:

Year:  2021        PMID: 34272590     DOI: 10.1007/s00330-021-08174-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  41 in total

Review 1.  Consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; P A Low; N Quinn; A Albanese; Y Ben-Shlomo; C J Fowler; H Kaufmann; T Klockgether; A E Lang; P L Lantos; I Litvan; C J Mathias; E Oliver; D Robertson; I Schatz; G K Wenning
Journal:  J Neurol Sci       Date:  1999-02-01       Impact factor: 3.181

Review 2.  Neuropathology underlying clinical variability in patients with synucleinopathies.

Authors:  Glenda M Halliday; Janice L Holton; Tamas Revesz; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-07-01       Impact factor: 17.088

Review 3.  Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes.

Authors:  M Stacy; J Jankovic
Journal:  Neurol Clin       Date:  1992-05       Impact factor: 3.806

Review 4.  Parkinsonism plus syndrome--a review.

Authors:  K Mitra; P K Gangopadhaya; S K Das
Journal:  Neurol India       Date:  2003-06       Impact factor: 2.117

5.  Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy.

Authors:  J Schwarz; S Weis; E Kraft; K Tatsch; O Bandmann; P Mehraein; T Vogl; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

6.  Quantitative susceptibility mapping differentiates between parkinsonian disorders.

Authors:  Henrik Sjöström; Tobias Granberg; Eric Westman; Per Svenningsson
Journal:  Parkinsonism Relat Disord       Date:  2017-09-01       Impact factor: 4.891

7.  Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging.

Authors:  A E Lang; T Curran; J Provias; C Bergeron
Journal:  Can J Neurol Sci       Date:  1994-11       Impact factor: 2.104

8.  T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease.

Authors:  Eduard Kraft; Claudia Trenkwalder; Dorothee P Auer
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

9.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

10.  Putaminal hypointensity in the parkinsonian variant of multiple system atrophy: simple visual assessment using susceptibility-weighted imaging.

Authors:  Jae-Hyeok Lee; Seung-Kug Baik
Journal:  J Mov Disord       Date:  2011-10-30
View more
  2 in total

Review 1.  Neuroimaging at 7 Tesla: a pictorial narrative review.

Authors:  Tomohisa Okada; Koji Fujimoto; Yasutaka Fushimi; Thai Akasaka; Dinh H D Thuy; Atsushi Shima; Nobukatsu Sawamoto; Naoya Oishi; Zhilin Zhang; Takeshi Funaki; Yuji Nakamoto; Toshiya Murai; Susumu Miyamoto; Ryosuke Takahashi; Tadashi Isa
Journal:  Quant Imaging Med Surg       Date:  2022-06

2.  Diagnostic Value of Magnetic Resonance Susceptibility-Weighted Imaging Scanning in Different Types of Early Prostate Cancer.

Authors:  Ruihui Gao; Jiayuan Liu; Hengcheng Zhu
Journal:  Scanning       Date:  2022-05-23       Impact factor: 1.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.